EUVIMEDEUVIMED entdecken
Open Access

PDCD10/CCM3, a potential target for pancreatic ductal adenocarcinoma?

Hendrik Ungefroren iD

Clinical Science · 2025

DOI: 10.1042/cs20241916 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Science, 2025. Verfasst von Hendrik Ungefroren. Beteiligte Einrichtung: First Department of Medicine, University Hospital Schleswig-Holstein (UKSH), and University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Apoptosis Regulatory Proteins, Pancreatic Neoplasms, Proto-Oncogene Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant progression of pancreatic ductal adenocarcinoma (PDAC) is driven by transforming growth factor (TGF)-β1 through extensive cross-talk with other signalling pathways. Prompted by the observation that the ubiquitous protein programmed cell death 10 (PDCD10) is more abundantly expressed in PDAC tumour tissue compared with normal pancreas and highly correlated with reduced patient survival, authors examined its function as a modulator of TGF-β signalling in PDAC. Cytotoxicity assays with PDAC-derived tumour cell lines, PaTu8902 (DPC4+/+) and PaTu8988t (DPC4-/-) engineered to homozygously lack PDCD10 showed that PDCD10 renders cells more chemoresistant to anticancer drugs. Moreover, PDCD10 promoted TGF-β1-dependent proliferation by inactivating the retinoblastoma 1 protein (pRb) via a SMAD4-dependent pathway, and TGF-β1-driven EMT by increasing ERK1/2 activation via a non-SMAD4 pathway. Phosphorylation of pRB and ERK by PDCD10 is facilitated by binding of PDCD10 to MST4. Targeting PDCD10 in PDAC patients may represent a promising new strategy to improve TGF-β targeted therapies

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalApoptosis Regulatory ProteinsPancreatic NeoplasmsProto-Oncogene ProteinsMembrane ProteinsHumansCell Line, TumorSmad4 ProteinTransforming Growth Factor beta1Cell ProliferationSignal TransductionDrug Resistance, NeoplasmRetinoblastoma ProteinAntineoplastic Agents

Stichwörter der Autor:innen

EMTERKPDACPDCD10ProliferationSMAD4TGF-βpRb

Substanzen

Apoptosis Regulatory ProteinsProto-Oncogene ProteinsPDCD10 protein, humanMembrane ProteinsSmad4 ProteinTransforming Growth Factor beta1SMAD4 protein, humanRetinoblastoma ProteinAntineoplastic Agents

Autor:innen und Institutionen

  • First Department of Medicine, University Hospital Schleswig-Holstein (UKSH), and University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany.

ORCID-Profile: Hendrik Ungefroren

Zitieren

APA

Ungefroren, H. (2025). PDCD10/CCM3, a potential target for pancreatic ductal adenocarcinoma?. Clinical Science. https://doi.org/10.1042/cs20241916

Vancouver

Ungefroren H. PDCD10/CCM3, a potential target for pancreatic ductal adenocarcinoma?. Clinical Science. 2025. doi:10.1042/cs20241916

BibTeX
@article{Ungefroren2025,
  author = {Ungefroren, Hendrik},
  title = {PDCD10/CCM3, a potential target for pancreatic ductal adenocarcinoma?},
  journal = {Clinical Science},
  year = {2025},
  doi = {10.1042/cs20241916}
}
Kostenlos starten →